全文获取类型
收费全文 | 41789篇 |
免费 | 2294篇 |
国内免费 | 149篇 |
学科分类
医药卫生 | 44232篇 |
出版年
2023年 | 318篇 |
2022年 | 414篇 |
2021年 | 1770篇 |
2020年 | 986篇 |
2019年 | 1083篇 |
2018年 | 1523篇 |
2017年 | 1095篇 |
2016年 | 1424篇 |
2015年 | 1457篇 |
2014年 | 2121篇 |
2013年 | 2383篇 |
2012年 | 3402篇 |
2011年 | 3311篇 |
2010年 | 1976篇 |
2009年 | 1566篇 |
2008年 | 2184篇 |
2007年 | 2231篇 |
2006年 | 2013篇 |
2005年 | 1774篇 |
2004年 | 1630篇 |
2003年 | 1398篇 |
2002年 | 1176篇 |
2001年 | 779篇 |
2000年 | 713篇 |
1999年 | 596篇 |
1998年 | 274篇 |
1997年 | 216篇 |
1996年 | 222篇 |
1995年 | 189篇 |
1994年 | 157篇 |
1993年 | 132篇 |
1992年 | 349篇 |
1991年 | 335篇 |
1990年 | 357篇 |
1989年 | 330篇 |
1988年 | 286篇 |
1987年 | 240篇 |
1986年 | 235篇 |
1985年 | 228篇 |
1984年 | 174篇 |
1983年 | 123篇 |
1982年 | 69篇 |
1981年 | 74篇 |
1980年 | 66篇 |
1979年 | 109篇 |
1978年 | 71篇 |
1977年 | 88篇 |
1976年 | 65篇 |
1973年 | 62篇 |
1971年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 22 毫秒
1.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
2.
3.
4.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
5.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections. 相似文献
6.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
7.
8.
B Maybury A Powell-Chandler N Kumar 《Annals of the Royal College of Surgeons of England》2015,97(3):e37-e38
We report two British cases of liver abscess, due to Klebsiella pneumoniae and associated with synchronous infection elsewhere, which required liver resection for definitive treatment. They illustrate the geographic spread of aggressive K pneumoniae liver infection and demonstrate the importance of early aggressive treatment. 相似文献
9.
Monique G. Kumar M.Phil. M.D. Heather Ciliberto M.D. Susan J. Bayliss M.D. 《Pediatric dermatology》2015,32(2):198-200
Pediatric trachyonychia is an acquired nail disease that can cause distress to families. It is a poorly understood disease, and long‐term follow‐up data are lacking. We present an institutional review of 11 children with isolated pediatric trachyonychia followed over time. Children with the diagnosis of pediatric trachyonychia were identified and invited to participate. Pictures were taken on follow‐up and a questionnaire was answered. Exclusion criteria include having another diagnosis at the initial visit that causes nail dystrophy. Eleven patients with the diagnosis of pediatric trachyonychia were available for follow‐up. The mean age of appearance was 2.7 years (range 2–7 yrs) and the average follow‐up was 66 months (range 10–126 mos). Nine patients were treated with potent topical corticosteroids, one used only petrolatum, and one took vitamin supplements. One patient was found to have an additional skin and hair diagnosis of alopecia areata on follow‐up. On follow‐up, 82% noted improvement of the nails, whereas 18% noted no change. A majority of cases of pediatric trachyonychia are isolated and improve with time, regardless of treatment. 相似文献
10.
Gokhlesh Kumar Subhodeep Sarker Simon Menanteau-Ledouble Mansour El-Matbouli 《Parasitology research》2015,114(6):2301-2308